Univ. Lyon, CarMeN, INSERM U1060, INSA de Lyon, INRA U1397, F-69621, Villeurbanne, France; Hospices Civils de Lyon, Department of Nephrology, Hôpital E. Herriot, Lyon, F-69003, France.
Univ. Lyon, CarMeN, INSERM U1060, INSA de Lyon, INRA U1397, F-69621, Villeurbanne, France.
Biochimie. 2018 Jan;144:1-8. doi: 10.1016/j.biochi.2017.09.018. Epub 2017 Oct 5.
Chronic kidney disease is associated with the accumulation of a large range of uremic retention solutes as referred to as uremic toxins. Some of these compounds belong to the group of Protein Bound Uremic Toxins (PBUT) due to their tight interactions with plasma proteins and especially serum albumin. These PBUT therefore exist in the bloodstream into two forms: a major bound (and non-diffusible) fraction and a minor free fraction. As a result, these compounds are poorly removed by most of the renal replacement therapies (such as hemodialysis) and their concentration can hardly be decreased in end-stage renal disease patients. An increase of the free fraction of PBUT could be achieved using chemical displacers that could compete with PBUT for binding to serum albumin. This review summarizes and discusses the interest of chemicals displacers as a valuable option to enhance PBUT removal in CKD patients.
慢性肾脏病与大量尿毒症潴留溶质的积累有关,这些溶质被称为尿毒症毒素。其中一些化合物属于蛋白结合尿毒症毒素(PBUT)的范畴,因为它们与血浆蛋白,特别是血清白蛋白紧密结合。这些 PBUT 因此以两种形式存在于血液中:主要结合(和不可扩散)部分和次要游离部分。因此,这些化合物很难通过大多数肾脏替代疗法(如血液透析)去除,并且它们的浓度在终末期肾病患者中很难降低。使用可以与血清白蛋白竞争结合的化学置换剂,可以增加 PBUT 的游离部分。这篇综述总结并讨论了化学置换剂作为增强 CKD 患者 PBUT 清除的一种有价值选择的意义。